Bavarian Nordic
Bavarian Nordic
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Active, not recruiting | Phase 3 | 2026-09-30 | NCT07003984 | |
| Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Recruiting | Phase 4 | 2026-09-28 | NCT06928753 | |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Active, not recruiting | Phase 3 | 2026-08-07 | NCT06007183 | |
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults | Alphavirus infectious disease, Infections, Mosquito-Borne Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, chikungunya, vector-borne disease, viral infectious disease | Recruiting | Phase 3 | 2026-06-29 | NCT07467707 | |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC | DNA Virus Infections, Infections, milker's nodule, monkeypox, non-human animal disease, non-human primate disease, rodent disease, smallpox, viral infectious disease | Active, not recruiting | Phase 3 | 2026-04-29 | NCT06844487 | |
| Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells | DNA Virus Infections, Infections, milker's nodule, monkeypox, non-human animal disease, non-human primate disease, rodent disease, viral infectious disease | Active, not recruiting | Phase 2 | 2026-04-08 | NCT07199569 | |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC | DNA Virus Infections, Infections, milker's nodule, monkeypox, non-human animal disease, non-human primate disease, rodent disease, smallpox, viral infectious disease | Active, not recruiting | Phase 3 | 2026-01-30 | NCT06844500 | |
| Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections | DNA Virus Infections, Infections, milker's nodule, monkeypox, non-human animal disease, non-human primate disease, rodent disease, viral infectious disease | Active, not recruiting | Phase 2 | 2025-11-24 | NCT06549530 | |
| A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine | Alphavirus infectious disease, Encephalitis, Arbovirus, Encephalitis, Viral, Encephalomyelitis, Equine, Infections, Mosquito-Borne Diseases, Neuroinflammatory Diseases, RNA Virus Infections, Togaviridae infectious disease, arbovirus infection, brain disorder, central nervous system disorder, central nervous system infectious disorder, encephalitis, encephalomyelitis, infectious encephalitis, nervous system disorder, vector-borne disease, viral infection of central nervous system, viral infectious disease | Active, not recruiting | Phase 2 | 2025-10-01 | NCT06899802 |